Acrivon Therapeutics’ $99.4 Million Initial Public Offering

Goodwin Procter advised the underwriters on the deal.Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that…

This content is for members only.
Login to Read More Join Now
Martina Bellini

Author: Martina Bellini

This content is for members only.
Login to Read More Join Now